Health and Human Sciences Faculty Works

Health and Human Sciences

2020

Heart Rate Variability and Cardiovascular Adaptations Among
Cancer-Survivors Following a 26-Week Exercise Intervention
Heather P. Tarleton
Loyola Marymount University, heather.tarleton@lmu.edu

Follow this and additional works at: https://digitalcommons.lmu.edu/hhsc_fac
Part of the Community Health Commons, Other Medicine and Health Sciences Commons, and the
Other Public Health Commons

Recommended Citation
Silvie Grote DrPH, Jeanette M. Ricci MS, Salem Dehom PhD, Naomi Modeste DrPH, Diadrey-Ann Sealy
PhD, and MS, MPAP Heather P. Tarleton PhD. 2020. “Heart Rate Variability and Cardiovascular
Adaptations Among Cancer-Survivors Following a 26-Week Exercise Intervention.” Integrative Cancer
Therapies 19 (October). doi:10.1177/1534735420969816.

This Article is brought to you for free and open access by the Health and Human Sciences at Digital Commons @
Loyola Marymount University and Loyola Law School. It has been accepted for inclusion in Health and Human
Sciences Faculty Works by an authorized administrator of Digital Commons@Loyola Marymount University and
Loyola Law School. For more information, please contact digitalcommons@lmu.edu.

969816

research-article20202020

ICTXXX10.1177/1534735420969816Integrative Cancer TherapiesGrote et al

Exercise and Cancer Treatment - Research Article

Heart Rate Variability and
Cardiovascular Adaptations
Among Cancer-Survivors Following a
26-Week Exercise Intervention

Integrative Cancer Therapies
Volume 19: 1–11
© The Author(s) 2020
Article reuse guidelines:
sagepub.com/journals-permissions
https://doi.org/10.1177/1534735420969816
DOI: 10.1177/1534735420969816
journals.sagepub.com/home/ict

Silvie Grote, DrPH1, Jeanette M. Ricci, MS2, Salem Dehom, PhD3,
Naomi Modeste, DrPH3, Diadrey-Ann Sealy, PhD4,
and Heather P. Tarleton, PhD, MS, MPAP5

Abstract
Cardiotoxicity as a result of cancer treatment contributes to autonomic dysfunction and decreased cardiorespiratory
fitness among cancer survivors. These deleterious cardiovascular outcomes reduce the survival prognosis for cancer
patients and contribute to poor quality of life among survivors. Exercise interventions have been shown as effective in
mitigating treatment-related side effects. However, previously published interventions have not explored the potential
for improvement in autonomic dysfunction (heart rate variability, HRV). This study examined cardiovascular adaptations
in cancer survivors (n = 76) who participated in a 26-week intervention consisting of combined aerobic and resistance
training (CART). The most noteworthy improvements occurred during the first 13 weeks of training and were maintained
throughout the end of the 26-week period. HRrest improved from baseline (PRE) to the midpoint (MID) (P = .036) and
from PRE to POST timepoints (P = .029). HRV and VO2max did not initially appear to change in response to CART.
However, after stratification on time since treatment, participants who were 5 or more years from their last treatment
experienced improvements (ie increase) in the HRV characteristic of HF power (P = .050) and also in VO2max (P =.043),
when compared to those experiencing less than 5 years of time since their last treatment. These findings highlight a
need for more attention to address the cardiorespiratory deficits experienced by those who have recently completed
cancer treatment. In conclusion, the CART intervention is effective in improving cardiorespiratory fitness and autonomic
dysfunction. The structure of the intervention is feasible for cancer survivors to continue with at home, using minimal
resources, and without supervision. This at-home model may be even more acceptable to recent survivors that may be
homebound immediately following treatment.
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Introduction
Cardiovascular disease ranks second as the leading cause of
death among individuals who underwent cancer treatment.1
Cardiotoxicity can be induced among cancer survivors by
chemotherapeutic agents and by radiation.2,3 Cardiotoxicity
appears as damage to the heart muscle, arrhythmias, cardiac
ischemia, pericardial disease and heart failure.4 As a result
of cardiotoxicity, cancer patients and survivors may experience a disruption of vagal regulation (ie autonomic dysfunction) and a decrease in cardiorespiratory fitness.5,6
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Regular exercise participation, including combined aerobic
and resistance exercise, may promote adaptations in vagal
tone and cardiorespiratory fitness among cancer survivors.
Disruption of vagal tone, also known as autonomic dysfunction, can be measured as a detrimental change in heart
rate variability (HRV) and/or an increase in resting heart
rate (HRrest). Changes in HRV and HRrest may not be perceived by an individual cancer survivor as an immediate
concern, however, the long-term impact is deleterious and
can contribute to increased mortality among cancer survivors as well as an increase in daily fatigue.3,6,7 Autonomic
dysfunction is associated with reduced parasympathetic
efficacy and increased sympathetic overdrive, which can
negatively affect heart health by increasing cardiovascular
strain and increasing the risk for premature death.8 Analysis
of HRV is the standard autonomic regulation assessment
method and allows for the quantification of variances in the
sinus rhythm.
HRV can be expressed using a frequency domain method
as different spectrum powers to compare parasympathetic
and sympathetic modulation.9 Specifically, low frequency
(LF) power (ms2) indicates both sympathetic and parasympathetic control and high frequency (HF) power is the
“respiratory sinus arrhythmia” and indicates primarily parasympathetic control.10,11 Increases in HF power measurements have been observed to correlate with resting
bradycardia (low resting heart rate), improved physical fitness, and a decreased risk for cardiovascular events.12,13
Given that increased parasympathetic control signifies
improved heart health, an improvement in HRV is indicated
by an increase in HF power (parasympathetic control) or a
decrease in the LF/HF power ratio.9,14 Measures of HRV
and HRrest have been associated with physical fitness in
healthy populations, but vagal control adaptations in
response to exercise in cancer survivors are not well understood.15 The expected exercise-related improvements in
vagal tone may be salient in cancer survivors given the
long-term effects of cardiotoxicity on morbidity and mortality in this population.
In addition to vagal tone, disruption of cardiorespiratory
fitness is often the most reported cardiovascular consequence of cancer treatment because of fatigue and the
reduced ability to partake in activities requiring higher metabolic demands.16 Further, cardiorespiratory fitness is a predictor of cancer-related mortality.16 Cardiorespiratory
fitness (VO2max) can be measured directly or indirectly, and
the latter can be carried out by assessment of maximal effort
or estimated from submaximal values. Using submaximal
exercise is a well-established practice for assessment of
older individuals and individuals with a history of chronic
conditions, such as cancer.17,18 Previously published studies
support the efficacy of aerobic exercise prescription in
improving cardiorespiratory fitness among cancer survivors
post-treatment.19 However, less is known regarding the
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benefits of a combined aerobic and resistance training
(CART) intervention among cancer survivors on cardiorespiratory fitness. HRV is understudied in general in cancer
patients/survivors and, specifically, there is a paucity of
research on the effect of CART on HRV in this population.
Expanding the current understanding of cardiovascular
adaptation among cancer survivors beyond HRrest and cardiorespiratory fitness to include HRV will provide oncologists, physiatrists, and clinical exercise physiologists with a
more comprehensive assessment of the long-term cardiovascular prognosis for their patients. Furthermore, exploring the potential for changes in both vagal tone and
cardiorespiratory fitness in response to a CART intervention will align with the intent of the current American
College of Sports Medicine (ACSM) recommendations for
weekly bouts of both aerobic exercise and resistance
training.
The psychosocial and physiological benefits of regular
exercise among cancer survivors are well documented,
including improvements in quality of life, body composition, cardiorespiratory fitness (ie VO2max), and insulin sensitivity.19 Initially, the majority of exercise interventions
among cancer survivors focused on aerobic exercise and its
relationship with improved cardiorespiratory fitness and
body composition.19 However, resistance training should be
an integral component when designing exercise interventions for cancer survivors to combat the muscle atrophy
associated with most cancer treatments.20 Accordingly, the
utilization of CART protocols have increased, with the
majority of studies involving participants performing aerobic and resistance training on separate days or include aerobic exercise followed by a resistance training circuit of
traditional strength exercises (ie leg press, chest press,
seated row).21-23 These CART interventions among cancer
survivors have demonstrated significant improvements in
cardiorespiratory fitness,24,25 yet there are potential limitations to the sustainability of a traditional gym-based CART
approach. The gym-based protocols often include a high
training volume (intensity and frequency) and participant
time commitment, require specialized equipment, and are
individualized which means that the important element of
social support found in partnered or group-exercise is often
missing. Furthermore, studies that have implemented more
feasible training protocols such as body-weight resistance
exercises (ie crunches, burpees), may not be suitable for
cancer survivors with severe physical limitations.26
Overall, there is a need to determine the efficacy of feasible CART protocols that are appropriate for cancer survivors at various post-treatment stages and that can be
implemented in group or community-based settings. The
pilot study presented herein aims to address this need by
examining cardiovascular adaptations, including vagal
tone, heart rate variability and cardiorespiratory fitness,
among cancer survivors following a 26-week CART
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intervention administered in a group setting. First, we
hypothesize that participants will experience significant
improvements in vagal tone (ie HRV and HRrest) and cardiorespiratory fitness (ie VO2max) at mid- and post-intervention
timepoints. Second, we hypothesize that in light of the cardiotoxic effects of treatment, those individuals with a
shorter time since treatment cessation will experience less
improvement in vagal tone and cardiorespiratory fitness
compared to those who have reached the 5 or more years
milestone for treatment cessation.

Methods
Overview of the Intervention
The Improving Physical Activity After Cancer Treatment
(IMPAACT) Study used an exercise prescription of combined aerobic and resistance training (CART) with the addition of core strengthening and flexibility. Primary outcomes
were measured at 3 timepoints over a 26-week intervention
period and included baseline-to-midpoint and midpoint-topost-intervention changes in vagal tone and cardiorespiratory fitness by measuring HRV (Low Frequency Power,
High Frequency Power, LF/HF ratio), HRrest, and VO2max in
cancer survivors. The study protocol was approved by the
Institutional Review Board at Loyola Marymount University
and the State of California Committee for the Protection of
Human Subjects.

Participants
Cancer survivors were recruited using the Los Angeles
Cancer Surveillance Program as well as convenience sampling and physician referral. Volunteers provided written
informed consent to participate in the study and were asked
to complete a questionnaire that used a closed-question
structure to collect information pertaining to demographic
characteristics, medical history, and health behaviors.
Volunteers were excluded if at least 1 of the following conditions was present: (1) recurrent cancer or new primary
diagnosis, (2) currently undergoing chemotherapy, (3) had
suffered myocardial infarction or stroke within 1 year of
enrollment date, (4) had history of fainting while exercising, (5) had history of chest pain or shortness of breath as a
result of physical activity, and (6) had lymphedema or
inflammation of lower extremities or pelvis. Prior to the
intervention, participants were asked to inform their physicians of their planned participation and to review the exercise and assessment protocols.

Intervention Design
The IMPAACT Study incorporated a CART program consisting of one-hour sessions, offered 3 times per week, for
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26 weeks at an academic facility. Each session included
20 minutes of cardiorespiratory training, 30 minutes of circuit-style resistance training and balance exercises, and
10 minutes of static and dynamic stretching. A Certified
Clinical Exercise Physiologist® and other study personnel
certified by the American College of Sports Medicine
(ACSM) designed the program according to the ACSM
Guidelines for Exercise for Cancer Survivors.27 Participants
wore heart rate monitors during each session and monitored
their exertion based on prescribed individual intensity of
the training heart rate zone. In combination with medical
history and current level of physical activity and aerobic
fitness, each participant’s target heart rate zone (% of heart
rate reserve) was derived from the Karvonen formula, using
age-predicted HRmax.
Participants engaged in cardiorespiratory training by
either walking/jogging outdoors or using a stationary bike
or elliptical machine indoors to reach their personalized
target heart rate zone. The designated route for walking/
jogging was mapped out for participants on an academic
campus in close proximity to the academic circuit/strength/
flexibility training facility and was without incline, obstacles, or trip hazards. The route was designed as a one-third
of a mile loop with the beginning of the loop at the entry
point to the academic training facility. Initial heart rate
zone prescription for all participants was 35% to 50%
depending on clinical/medical history and functional and
physical ability as determined by baseline testing. Over
the course of the study, heart rate zones were reviewed
once weekly and adjusted every 2 weeks with an average
change of 0% to 5%.
The circuit-training portion followed the cardiorespiratory training and included 10 stations of alternating upper
and lower body resistance-based exercise, balance activities, and vibration plates. During the first 2 weeks of training, participants completed 2 sets of the 10 exercise stations
for a total of 2 minutes per station with 60-second transition/rest periods between stations. Longer time at each station allowed for participants to familiarize themselves with
exercise technique and allowed the trainers to determined
most appropriate resistance/modality at each station. The
training progressed toward 3 sets of the 10 exercise stations
with each station performed for 45 seconds with a 20-second transition/rest period between stations. Variations in
exercise intensity were provided at each resistance exercise
station including different band strengths or dumbbell
weights. Exercise intensity was monitored via heart rate and
participants were encouraged to maintain their target heart
rate zones throughout the cardiovascular and resistance
training portions. Further, principles of overload and progression were considered and intensity levels (repetitions,
sets, weight, and color of band or tubing) were recorded on
participant’s exercise cards. Progression of intensity was no
more than 5% and 10% for upper body and lower body
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exercises per week, respectively. Sample exercises included
in the exercise circuit were resistance band rows, squats,
forward/backward and lateral lunges and stepping, abdominal exercise variations, push-ups, or overhead press.
Participants used resistance bands and tubing or light hand
and ankle weights to increase the load. Balance exercises
included a variety of movements that targeted visual, vestibular and somatosensory systems, postural control and
strategies, as well as center of gravity control and gait pattern variations exercises. Two stations included vibration
plates on which the participants progressed from standing
with knees slightly bent to partial and full squats and calf
raises based on tolerance. All exercises were designed to
potentially mediate deficits in body composition, aerobic
fitness, muscular strength, bone density and neuropathy,
conditions known to be present among cancer survivors.28
All participants were offered customized modification at
each station depending on their physical ability. The circuit
session concluded with a 10-minute period of approximately 5 core exercises performed for 2 sets for 30 seconds
each (ie chair leg raises, curl-ups, seated side bends) followed by 5 minutes of static stretching of major muscle
groups with participants choosing to stretch while seated or
while standing with support from a chair.

Fidelity to the Intervention
Attendance was recorded during each exercise session to
measure program adherence. Participants self-monitored
prescribed heart rate zones by wearing heart rate monitors
during the entire exercise session. Throughout the intervention the prescribed zones began at 35-50% of participants’
heart rate reserve, with the individual range increasing based
on participant’s ability to maintain the intensity, their perceived exertion, and regular attendance. Participants strove
to exercise continuously during the duration of each station
while maintaining their intensity within the prescribed heart
rate zones. The ratio of trainers-to-participants at each session was minimally 1:4. Trainers were a consistent source of
encouragement and could regularly remind participants to
check their heart rate monitors to maintain their exertion levels and to breathe rhythmically without holding the breath.
Trainers also helped participants prepare to transition to the
next station during circuit training. Participants were able to
walk alone or with 2 or more walking buddies during the
aerobic exercise portion. Participants were paired with 1 or
2 other people at each circuit station and the static and
dynamic stretches were performed as a group.
For each session, 1 trainer held the responsibility of circulating among participants and recording heart rates and
exertion levels at the beginning of the aerobic session and at
the beginning of each lap that participants made on the designated walking/jogging route. These data were collected
again at the end of the aerobic session and prior to the start
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of the circuit training, with participants being reminded to
continue to walk around and keep their legs moving while
they had a water break. At the end of the circuit training session and prior to the core/flexibility session another round
of data collection occurred. The last point of data collection
took place at the end of the core/flexibility session.

Outcome Measures
Vagal tone and HRV. Prior to testing, participants were
instructed to abstain from caffeine-containing foods and
drinks and other stimuli known to affect heart rate as well as
vigorous exercise at least 24 hours before assessment and
were asked to refrain from large meals 3 hours prior to testing. No participants were prescribed hormonal treatments
over the course of the study and 6 participants were prescribed beta blockers. Participants completed exercise testing while on their prescribed medications and researchers
ensured participants were on the same dose of medication at
all testing timepoints. Further, participants completed testing at the same time of day for pre, mid, and post testing
timepoints. Upon arriving at the laboratory, participants
were familiarized with testing procedures. To assess resting
heart rate, (HRrest), participants rested supine in a laboratory
room with decreased sensory stimulation for a 10-minute
period. Breathing was paced at 12 cycles of inhalations and
exhalations per minute using a metronome to minimize the
effect of respiratory influence. The 10-minute recording
started once the participants comfortably synced their
breath with metronome and a 7-minute period was eventually evaluated; it was selected by excluding recordings with
large R-R interval outliers and by adhering to R-R interval
equidistance.29 HRrest was determined as the lowest number
of beats per minute (bpm) during the 10-minute period and
was recorded from a Polar RS800CX (Polar Electro, Lake
Success, NY) training computer. R-R intervals were measured simultaneously on the same device and were then
transferred to the Kubios software package (version 2.2) for
analysis of HRV.30 HRV data was pre-processed within
Kubios to automatically remove artifacts and ectopic beats
using a medium (0.25 seconds) threshold value for each participant. Specific outcome measures of HRV include LF
power (ms2), HF power (ms2), and LF/HF ratio (ms2).
Cardiorespiratory fitness. Cardiorespiratory fitness (VO2max)
was estimated from a submaximal YMCA protocol on a
cycle ergometer.31 The YMCA test has demonstrated strong
criterion validity against a maximal treadmill test in adults
(r = 0.77).31 A validated submaximal exercise test was chosen for this study instead of a maximal exercise test because
of participants’ history of cancer and cancer treatment and
self-reporting of reduced exercise capacity and physical
functioning during recruitment and screening.32 The YMCA
test is an incremental exercise test during which the heart
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rate response is logged in response to progressive resistance
load at a cadence of 50 revolutions per minute (rpm). The
test concludes successfully when the participant reaches 2
steady-state periods marked by heart rate readings of no
more than 6 beats apart per minute within an intended range
of 110 bpm and 85% of the age-predicted maximal heart
rate. Participants maintained a cadence of 50 rpm during a
cool-down period.

Statistical Analysis
Descriptive statistics are given as mean ± standard deviation for participant characteristics or mean with 95% confidence intervals for outcome measures, and number with
percentage for qualitative variables. Normality was verified
for all variables using histograms and box-plots. Time since
treatment was collected as a continuous variable (years) and
coded as a categorical variable (<5 years and ≥5 or more
years).33,34 Given the emphasis on the cardiotoxicity associated with chemotherapy and radiation, the treatment variable was collapsed into a two-category variable of
chemotherapy and/or radiation exposure versus no chemotherapy/radiation exposure. Mann-Whitney U test procedure was used to examine whether there was any difference
in the change of each outcome at different timepoints by
race and treatment type. Separate repeated measures analysis of variance (ANOVA) tests were used to determine
changes in outcome measures across the 3 timepoints (PRE,
MID, and POST). Sample size for each analysis may vary
as a result of incomplete assessment data. Post hoc tests
were done on least-squares means using a Tukey adjustment for multiple comparisons. Log transformation was
used when the assumptions were not met. For outcome
measures that improved significantly across time points, a
Pearson Chi-square test was performed to determine the
proportion of participants that improved measures of cardiovascular function from PRE to MID and from PRE to
POST timepoints for groups attending ≤50% of sessions
and those attending >50% of sessions throughout the intervention. All statistical tests were performed at an α = 0.05
significance level. Statistical analyses were performed
using SPSS (Version 26; IBM Corporation 1989, 2019) and
SAS (Version 9.3; SAS Institute Inc.).

Results
Demographics
Participant demographics for the pooled cohort (n = 76) at
baseline are shown in Table 1. Demographics for the 2 individual cohorts have been published previously.34 Participants
had a mean age of 62.9 ± 10.1 years and reported their primary cancer site as follows: breast (39.5%), endometrial
(15.8%), gynecological (10.5%), colorectal (9.2%),
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Table 1. Participant Characteristics at Baseline for the
IMPAACT Study (n = 76).
Item
Gender
Race
Time since
treatment
(TST)
Treatment type

Category
Men
Women
White
Non-White
<5 years
≥5 years

Surgery/other
Chemotherapy/radiation
Smoking status* Never smoked >100
cigarettes or other
tobacco products
Other
Education*
Some college or less
College graduate
Sleep/night*
4 or less hours
5-6 hours
7 or more hours
Perceived
Good/OK
physical activity Needs improvement

n†

% of sample

7
69
49
27
36
33

9.2
90.8
64.5
35.5
52.2
47.8

25
51
51

32.9
67.1
69.9

22
18
57
1
43
31
30
45

30.1
24.0
76.0
1.3
57.3
41.3
40.0
60.0

*P < .05 between category groups.
†
Sample size is varied due to incomplete survey data.

Hodgkin’s lymphoma and uterine (5.3% each), melanoma
and thyroid (3.9% each), prostate (2.9%), and other (12.9%).
At baseline, our sample was characterized as overweight
with an average BMI of 28.5 ± 6.4 kg/m2.

Intervention Participant Adherence
Average exercise session attendance was 59.0 ± 18.1%,
with the lowest attendance rate at 11.3% and highest rate at
96.3%. Reasons for lack of attendance included musculoskeletal issues, injuries/accidents unrelated to exercise
intervention, vacations, return to treatment, or death unrelated to the exercise intervention. Number of sessions
attended (<50% vs ≥50%) in the intervention was similar
between White and non-White participants (P = .099).

Intervention-Associated Changes in Outcome
Measures
Participant changes in outcome measures from baseline/0 weeks (PRE), midpoint at 13 weeks (MID), and postintervention at 26 weeks (POST) are summarized in Table 2.
Vagal tone and HRV. HRrest improved from PRE to MID
(P = .036) and from PRE to POST timepoints (P = .029)
(Table 2). These improvements were not modified by treatment type (P = .965) or race (P = .488). When HRrest was
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Table 2. Change in Outcome Measures at Baseline, 13 weeks, and 26 weeks of an Exercise Intervention in Cancer Survivors.
PRE
Outcome measures
†

HRrest (bpm) *
VO2max (mL/kg/min)†
Low frequency (LF) power (ms2)†
High frequency (HF) power (ms2)†
LF/HF Power (ms2)†

MID

POST

(0 weeks)

n

(13 weeks)

n

(26 weeks)

n

71.1 (67.1, 75.3)
22.2 (20.0, 24.5)
269.4 (192.8, 376.5)
187.6 (125.4, 280.7)
1.4 (1.1, 1.8)

76
69
62
62
62

65.1 (62.1, 67.6)
21.5 (19.2, 24.0)
228.5 (162.6, 321.1)
196.1 (130.2, 295.4)
1.1 (0.9, 1.4)

63
57
60
60
60

64.8 (62.3, 67.5)
21.3 (18.8, 24.0)
203.1 (137.7, 299.5)
174.4 (109.2, 278.5)
1.1 (0.8, 1.5)

53
47
46
46
46

Percent of Participants
Experiencing Reduction

Data reported as mean (95% Confidence Interval): bpm = beats per minute. Sample size may vary due to the inability of a small number of participants
to complete the assessment battery.
†
Based on log transformed variable.
*Significant difference between PRE and MID and PRE and POST (P < .05).

60%

64%

62%
47%

Reduction in HRrest from
PRE to MID

44%

Reduction in HRrest from
MID to POST

≤50 % of Sessions Attended

62%

Reduction in HRrest from
PRE to POST

> 50 % of Sessions Attended

Figure 1. Percent of participants experiencing a reduction in resting heart rate (HRrest) from baseline (PRE) to 13 weeks (MID), from
MID to 26 weeks (POST), and from PRE to POST for participants attending ≤50% of sessions compared to participants attending
>50% of sessions.

examined across categories of participation frequency
(<50% sessions attended vs ≥50% sessions attended),
there was no modification of the observed change in HRrest
from PRE to MID (P =.703) or from PRE to POST timepoints (P = 1.000) (Figure 1). HRrest was also examined
across categories of time since treatment (<5 years TST,
≥5 years TST) and data are presented in Figure 2. A larger
percentage of participants in the ≥5-year TST group experienced an improvement (ie decrease) in HRrest from PRE to
MID timepoints, as compared to the <5 years TST group,
however, this difference was not statistically significant
(P = .778).
With regard to HRV outcomes (Table 2), there was no
observed change in LF power, HF power, or the LF/HF
power ratio from PRE to MID or from PRE to POST
(P > .050). Treatment type did not modify the observations for HF power (P = .710) or LF power (P = .678).
When race was considered, a suggested change was noted
for HF power (P > .075) between PRE to MID, but not for

LF power (P > .394). When time since treatment was
considered, a change was observed for HF power
(P = .050), reflecting that a greater number of participants
in the ≥5 year TST group experienced improvements (ie
increase) in HF power between PRE and MID timepoints
compared to cancer survivors in the <5 year TST group
(Figure 2). There was no observed difference in the number of participants demonstrating improvements (ie
decrease) in LF power between TST groups (P = .329)
(Figure 2).
Cardiorespiratory fitness. Changes in VO2max were not apparent from PRE to MID or from PRE to POST timepoints
(P >.05) (Table 2). VO2max across timepoints was not modified by race (P = .657) or treatment type (P = .732). In a Chi
Square analysis of time since treatment, more participants
in the ≥5-year TST group experienced improvements in
VO2max (P = .043) compared to participants in the <5-year
TST group (Figure 2).
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Percent of Participants
Experiencing Improvement
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63%

61%

58%

59%

59%

46%
30%

VO2max

28%

LF

TST < 5

HF
TST ≥ 5

HRrest

Figure 2. Percent of participants who demonstrated improvement in outcome measures from baseline (PRE) to 13 weeks (MID) for
participants within 5 years of treatment (TST < 5 years) compared to participants who received their last treatment 5 or more years
prior to study onset (TST ≥ 5 years).

Discussion
This pilot study examined cardiovascular adaptations (ie
HRV and cardiorespiratory fitness) following a 26-week
combined aerobic and resistance training (CART) intervention, implemented in a group setting. Improvements in outcomes were most prominent between the PRE to MID
timepoints, suggesting that the initiation of participation in
CART was most beneficial during the first 13 weeks of the
intervention. Changes in outcomes did not reach statistical
significance from MID to POST, which indicates that participants may have experienced a plateau effect in their training
adaptations. However, improvement in HRrest was progressed
during MID to POST timepoints and the improvements in
several outcomes from the PRE to MID training period were
sustained during the MID to POST training period.

Improvements in Vagal Tone
HRrest improved from PRE to MID timepoints, demonstrating improved cardiovascular function following our CART
intervention. Interestingly, improvements in HRrest did not
vary by treatment type, race, or time since treatment, suggesting that our CART program may be sensitive to elicit
improvements in cancer survivors independent of their time
since treatment status. Specifically, the decrease in HRrest
observed may be attributed to an improvement in parasympathetic modulation and/or improvements in cardiorespiratory fitness in our sample of cancer survivors.11 However, it
is difficult to attribute potential mechanisms to explain or
our findings given that there were no changes initially
observed for cardiorespiratory fitness or HF power (parasympathetic control) or LF power (parasympathetic/sympathetic control) across timepoints and no variation with

treatment type, time since treatment (cardiorespiratory fitness only), or race (LF power only). Nonetheless, the variation suggested with race for HF power should be explored
further to separate potential biological characteristics of
cardiovascular adaptation and race from external characteristics (eg psychosocial stressors) that may influence parasympathetic control and time since treatment.
In the current study, participants in the ≥5-year TST
group experienced the greatest improvement in HF power,
likely because they are further from the cardiotoxic effects
of treatment. Similar to our findings, Caro-Morán et al15
examined vagal tone in breast cancer survivors who were
less than 1 year from treatment cessation and demonstrated
significantly lower HF power among cancer survivors compared to age-matched controls. These differences in HRV
have been frequently attributed to cancer therapies that
include the anthracycline- and trastuzumab- containing regimens, or to new adjuvant cytotoxic (taxane-containing)
agents and hormonal regimens (aromatase inhibitors) in
which several of the participants in the present study completed.35 However, Cramer et al36 found that patients with
colorectal cancer had compromised vagal tone regardless of
whether they underwent chemotherapy or not, suggesting
that a different mechanism might negatively affect autonomic function. For example, vagal tone disparities may
resolve over time with a washing out of treatment effects
which may explain why participants longer from treatment
experienced greater improvements in parasympathetic control. Findings from this current pilot study are consistent
with the aforementioned studies in that: (a) the effect of
treatment appears to lag well into the survivorship period
with an eventual washout of cardiotoxicity after 5 or more
years, (b) treatment type does not appear to modify vagal
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tone and perhaps there is another determinant of the cancer
experience that is influencing HRV. Another potential
mechanism that may explain the lack of effect of exercise
on vagal tone is the intra-individual variability in daily HRV
measures. For example, participants completing cancer
treatment more recently may experience greater variability
and therefore using an isolated daily HRV measurement as
in the present study may have confounded the results.
Therefore, future research investigating the effects of exercise training on HRV among cancer survivors may complete more robust HRV analyses including weekly
coefficients of variation as performed in athlete monitoring
investigations37 to account for the high variability in recent
cancer survivors.

Improvements in Cardiorespiratory Fitness
Our study demonstrated no changes for VO2max across timepoints and no variation by race or treatment type. However,
similar to certain vagal tone outcomes, we observed a better
outcome for those survivors that are further from the cardiotoxic effects of treatment. In contrast to our findings, DieliConwright and colleagues demonstrated an increase in
estimated VO2max in breast cancer survivors following a
6-month aerobic and resistance training intervention with a
prescribed exercise intensity of 65-85% heart rate maximum.22 The inability to detect a change in cardiorespiratory
fitness in the current study may be attributed to our sample
size and/or to our use of a submaximal protocol for assessing VO2max. For example, some participants were unable to
match their efforts during the MID or POST YMCA submaximal bicycle tests due to physical limitations at the time
of assessment. Further, prescribed intensity for aerobic
exercise was individualized based on the current health status and physical limitations of the participant, and the intensity may not have been sufficient to elicit significant
improvements in VO2max comparable to previous studies
that utilized a higher exercise intensity.22

Limitations and Strengths
This pilot study’s sample size is small, however, it remains
comparable in size to other studies examining exercise
interventions in cancer survivors.38,39 The study is designed
as a prospective analysis of a single intervention group and
is limited by the absence of a control group. The study is
strengthened by a relatively long intervention period of
26 weeks, which allows for longitudinal assessment of individual progress at multiple, meaningful timepoints. Our
sample was heterogeneous in terms of types of cancer site,
however, researchers have previously reported that cancer
type did not affect exercise-mediated cardiovascular outcomes.40 Further, this study examined a more feasible
CART program implemented in a group-based setting
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compared to traditional gym-based CART programs requiring specialized equipment and a high training volume.22
The midpoint assessments took place at the conclusion
of the first 13-week training period and were followed by a
month-long break in supervised training due to the academic training setting and respect for observance of religious/ethnic holidays. Participants were provided with
at-home instructions for the CART intervention in order to
maximize intervention fidelity. The intervention at the academic facility was designed to be adaptable to a home setting and without reliance on specialized equipment or
spaces. As such, the at-home adaptations were identical to
those in the academic facility and participants were already
trained in the intervention protocol by participating for the
first 13 weeks. Participants were given resistance bands and
hand weights to use at home, along with a printed intervention protocol guidebook with pages to record daily progress
and HR monitor readings, and their own Polar watches/
chest straps. The month away from the supervised program
may have contributed to a lack of improvement in outcomes
during the MID to POST timepoints, but it did not have a
deleterious effect on the gains from the PRE to MID timepoints. Participant improvements noted at MID were maintained throughout the second 13 weeks of the training
program (MID through POST).
Further, leg fatigue or arthritic related complaints were
the most common reasons reported by the participants who
could not successfully finish YMCA submaximal test,
which resulted in unequal sample sizes at the assessment
timepoints. Our assessment experience raises a question
regarding the best way of determining cardiorespiratory fitness in a population of cancer survivors. It is challenging to
accommodate the varied ability levels coupled with a wide
age range in a highly heterogeneous group. Whereas the
walking mode can serve participants with higher mobility
or those unable to stay seated for longer periods of time (eg
patients treated for colorectal cancer), cycling provides a
safer mode for cancer survivors suffering from treatmentrelated balance issues.41

Conclusion and Practical Implications
This pilot study examined the effects of a CART intervention
on both cardiorespiratory fitness and vagal tone in cancer survivors. It is worth noting that the CART intervention was
acceptable to older cancer survivors that could be characterized as overweight and that self-reported a need to improve
their physical activity levels. Attendance among participants
varied, however, frequency of participation did not significantly change the intervention efficacy. This may be due to
the ease at which participants could self-monitor fidelity to
the intervention using a heart rate monitor and basic Likert
scale assessment of exertion, regardless of the type of exercise they were engaged in. In addition to the observed
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improvements in resting heart rate for cancer survivors in
response to CART, this study also demonstrates potential
synchronicity between improvements in cardiorespiratory
fitness and vagal tone (HF power/parasympathetic tone).
This study identifies a potential health disparity in the
gains in both cardiorespiratory fitness and vagal tone as a
result of proximity to treatment. Based on our findings,
future studies should focus on exercise prescriptions that
might be tailored to cancer survivors who have recently
completed treatment in order to reduce vagal tone disparities in a safe and efficacious manner. During recovery and
after cessation of physical activity, sympathetic withdrawal
coupled with increased vagal input helps the body return to
a resting state.42 HRV-guided training can help to individualize exercise prescriptions not only for athletes but also for
clinical populations. Enhanced levels of vagal input before
an exercise bout as well as sufficient recovery state, that is,
fully recovered vagal tone, both lead to better training
response.43 Whereas the current exercise guidelines for cancer survivors are comprehensive, the protocol does not
include the use of HRV as part of individualized exercise
prescription. As the scientific community continues to
explore the most effective forms of physical activity interventions, HRV lends itself to aid this process.38
The potential use of an at-home program as a “maintenance therapy” after an initial supervised intervention
increases the feasibility and scalability of CART to improve
cardiovascular adaptations among cancer survivors. At-home
interventions may also be implemented on virtual platforms
to encourage partnered or group exercise while mitigating
transportation barriers and restrictions on social distancing if
a cancer survivor is experienced immune compromise as a
treatment-related side effect.
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